Showing 850 results
-
Media Release /- FEATURE and JUNCTURE data show secukinumab delivered significant skin clearance at week 12(1,2)- Patients reported high satisfaction with self-administration of secukinumab pre-filled syringe or…
-
Media Release /- Designation supports the advancement of CTL019 to help address the unmet need of patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL)- The filing was submitted by the University…
-
Media Release /The study met the primary endpoint with objective response rates of 41.8% and 32.5% respectively in the 200 mg and 800 mg treatment arms(1,2)Basal cell carcinoma is the most common form of skin…
-
Media Release /Pivotal data in ALK+ NSCLC for Zykadia™; recently approved by US FDA, marking fastest oncology approval under Breakthrough Therapy designationFirst presentation of pivotal data from Phase III trial…
-
Media Release /- Study showed significantly more HF-REF patients on LCZ696 regimen were alive, had fewer hospitalizations than those given enalapril regimen(1)- On all-cause mortality, LCZ696 doubled the effect…
-
Media Release /-- LCZ696 significantly reduced cardiovascular deaths in head to head study against enalapril, in addition to current best treatment, in patients with HF-REF-- PARADIGM-HF is the largest heart…
-
Media Release /- Results of two Phase III psoriasis studies show secukinumab, the first psoriasis IL-17A inhibitor filed with regulatory bodies, met all co-primary and key secondary endpoints[1]- A statistically…
-
Media Release /- Biologics License Application (BLA) for secukinumab, a "first-in-class" IL-17A inhibitor, is currently under FDA review with an anticipated action date in early 2015- FDA Advisory Committee…
-
Media Release /- Preliminary study results show 27 of 30 pediatric and adult patients with relapsed/refractory (r/r) ALL (90%) experienced complete remissions with personalized cell therapy, CTL0191- Largest…
-
Media Release /Afinitor led to an unprecedented median overall survival of 44 months, which represents a clinically meaningful while not statistically significant improvement(1)Pancreatic NET (pNET) affects about 2…
